PlasmaGen Biosciences ('PlasmaGen'), a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, recently celebrated the official opening of the company's new manufacturing plant in Kolar, Bengaluru. This cutting-edge facility is spread across 8 acres and is made up of multiple connected, yet independently operable blocks that support various operations of the manufacturing process. The facility will significantly improve the supply-demand scenario for affordable blood-plasma derived products.

“PlasmaGen’s new facility is the latest example of our investment in the future – which includes advancing our growing capabilities in manufacturing plasma-derived products at scale,” said Vinod Nahar, Founder & Managing Director, PlasmaGen Biosciences. “At this facility, which also houses the largest R&D infrastructure and quality control lab in the blood plasma industry in the country, we aim to produce multiple plasma products like albumin, immunoglobulins and coagulation factors in our mission to be a trusted and leading Indian biopharmaceutical company, dedicated towards improving the health and quality of life of patients.”

While blood plasma products have been widely used in developed countries for several decades, emerging economies such as India are seeing a significant increase in their adoption due to increased physician awareness of their benefits, increased insurance penetration, rising affordability, and an increasing rate of immune deficiency disorders.

To effectively meet potential domestic demand, the WHO estimates that India will need to process 7 million litres of blood plasma (up from 1 million litres today). Furthermore, 91 countries rely on imported plasma-derived products, implying a massive opportunity for Indian manufacturers to effectively meet demand in emerging markets.